Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitiligo | 66 | 2025 | 123 | 25.960 |
Why?
|
Skin | 23 | 2024 | 357 | 7.080 |
Why?
|
Melanocytes | 17 | 2025 | 78 | 5.740 |
Why?
|
Hypopigmentation | 11 | 2023 | 18 | 5.580 |
Why?
|
Autoimmunity | 13 | 2025 | 223 | 3.580 |
Why?
|
CD8-Positive T-Lymphocytes | 13 | 2023 | 648 | 3.220 |
Why?
|
Autoimmune Diseases | 7 | 2025 | 220 | 2.600 |
Why?
|
Skin Pigmentation | 7 | 2021 | 29 | 2.580 |
Why?
|
Alopecia Areata | 6 | 2018 | 10 | 2.540 |
Why?
|
Janus Kinase Inhibitors | 4 | 2023 | 17 | 2.400 |
Why?
|
Immunotherapy | 4 | 2020 | 230 | 2.140 |
Why?
|
Chemokines | 4 | 2021 | 92 | 1.810 |
Why?
|
Interferon-gamma | 11 | 2024 | 551 | 1.790 |
Why?
|
T-Lymphocytes | 6 | 2025 | 983 | 1.750 |
Why?
|
Chemokine CXCL10 | 11 | 2023 | 56 | 1.680 |
Why?
|
Dermatology | 4 | 2023 | 70 | 1.640 |
Why?
|
Pyrazoles | 6 | 2022 | 64 | 1.620 |
Why?
|
Immunologic Memory | 6 | 2021 | 281 | 1.560 |
Why?
|
Humans | 86 | 2025 | 59282 | 1.490 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2022 | 207 | 1.470 |
Why?
|
Blister | 2 | 2024 | 17 | 1.460 |
Why?
|
Melanoma, Experimental | 2 | 2021 | 40 | 1.430 |
Why?
|
Receptors, CXCR3 | 5 | 2023 | 35 | 1.430 |
Why?
|
Skin Diseases | 4 | 2022 | 76 | 1.390 |
Why?
|
Animals | 37 | 2025 | 19601 | 1.260 |
Why?
|
Keratinocytes | 4 | 2023 | 63 | 1.220 |
Why?
|
Gene Expression Profiling | 4 | 2024 | 716 | 1.180 |
Why?
|
Disease Models, Animal | 11 | 2022 | 2046 | 1.150 |
Why?
|
Chemokine CXCL9 | 6 | 2023 | 24 | 1.060 |
Why?
|
Simvastatin | 2 | 2017 | 26 | 1.010 |
Why?
|
Mice | 24 | 2023 | 10251 | 1.000 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2017 | 168 | 0.980 |
Why?
|
Dermatitis, Irritant | 1 | 2024 | 4 | 0.940 |
Why?
|
Signal Transduction | 8 | 2020 | 2888 | 0.940 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2024 | 13 | 0.930 |
Why?
|
Ultraviolet Therapy | 5 | 2023 | 14 | 0.900 |
Why?
|
Lupus Erythematosus, Cutaneous | 2 | 2021 | 13 | 0.890 |
Why?
|
Pyrimidines | 7 | 2022 | 130 | 0.860 |
Why?
|
Immunity, Innate | 8 | 2021 | 765 | 0.770 |
Why?
|
RNA, Small Cytoplasmic | 1 | 2021 | 6 | 0.760 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2021 | 8 | 0.740 |
Why?
|
Receptors, CCR5 | 1 | 2021 | 56 | 0.740 |
Why?
|
Cancer Vaccines | 1 | 2021 | 46 | 0.730 |
Why?
|
Lupus Nephritis | 1 | 2021 | 33 | 0.720 |
Why?
|
Anti-Infective Agents | 1 | 2023 | 143 | 0.720 |
Why?
|
Nitriles | 5 | 2022 | 62 | 0.720 |
Why?
|
Biological Products | 1 | 2022 | 90 | 0.710 |
Why?
|
Cross-Priming | 1 | 2020 | 16 | 0.700 |
Why?
|
Hair Dyes | 2 | 2017 | 5 | 0.680 |
Why?
|
Epidermis | 2 | 2018 | 35 | 0.680 |
Why?
|
Immunity, Cellular | 4 | 2019 | 169 | 0.680 |
Why?
|
Interferon Type I | 2 | 2020 | 168 | 0.660 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 171 | 0.640 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 1151 | 0.640 |
Why?
|
Mice, Inbred C57BL | 10 | 2021 | 3220 | 0.630 |
Why?
|
Efficiency | 1 | 2019 | 37 | 0.630 |
Why?
|
Immunosuppressive Agents | 3 | 2022 | 365 | 0.610 |
Why?
|
Antibodies, Blocking | 1 | 2018 | 40 | 0.610 |
Why?
|
Adult | 18 | 2025 | 15663 | 0.600 |
Why?
|
Interleukin-15 | 1 | 2018 | 24 | 0.600 |
Why?
|
Male | 22 | 2025 | 27727 | 0.580 |
Why?
|
Melanoma | 1 | 2021 | 329 | 0.570 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 206 | 0.570 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 244 | 0.570 |
Why?
|
Skin Lightening Preparations | 1 | 2017 | 3 | 0.560 |
Why?
|
Lymphocyte Count | 1 | 2017 | 68 | 0.550 |
Why?
|
Stress, Physiological | 2 | 2016 | 185 | 0.540 |
Why?
|
Bullying | 1 | 2016 | 15 | 0.520 |
Why?
|
Phenols | 1 | 2017 | 74 | 0.520 |
Why?
|
Delivery of Health Care | 2 | 2023 | 407 | 0.520 |
Why?
|
Antibodies | 1 | 2017 | 179 | 0.520 |
Why?
|
Patient Satisfaction | 1 | 2019 | 412 | 0.500 |
Why?
|
Mice, Transgenic | 5 | 2021 | 1204 | 0.500 |
Why?
|
Melanins | 1 | 2015 | 21 | 0.490 |
Why?
|
Organ Specificity | 1 | 2016 | 182 | 0.490 |
Why?
|
Wnt Signaling Pathway | 1 | 2015 | 71 | 0.480 |
Why?
|
Female | 20 | 2025 | 30695 | 0.480 |
Why?
|
Hair | 1 | 2015 | 78 | 0.480 |
Why?
|
Young Adult | 7 | 2025 | 4266 | 0.470 |
Why?
|
Middle Aged | 12 | 2025 | 16310 | 0.470 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2021 | 620 | 0.460 |
Why?
|
Genetic Vectors | 1 | 2020 | 807 | 0.460 |
Why?
|
Severity of Illness Index | 8 | 2025 | 1479 | 0.460 |
Why?
|
Biomarkers | 4 | 2024 | 1305 | 0.460 |
Why?
|
Psoriasis | 2 | 2016 | 50 | 0.460 |
Why?
|
Quality of Life | 6 | 2025 | 1137 | 0.450 |
Why?
|
Adolescent | 7 | 2025 | 5822 | 0.450 |
Why?
|
Treatment Outcome | 11 | 2023 | 5283 | 0.430 |
Why?
|
Biopsy | 3 | 2024 | 411 | 0.420 |
Why?
|
Dermatologic Agents | 2 | 2024 | 20 | 0.410 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 91 | 0.400 |
Why?
|
Double-Blind Method | 5 | 2022 | 715 | 0.400 |
Why?
|
Kidney Tubular Necrosis, Acute | 1 | 2021 | 4 | 0.380 |
Why?
|
Ureteral Obstruction | 1 | 2021 | 13 | 0.380 |
Why?
|
Scleroderma, Localized | 2 | 2023 | 10 | 0.380 |
Why?
|
Genome-Wide Association Study | 3 | 2021 | 331 | 0.370 |
Why?
|
Suction | 2 | 2024 | 33 | 0.370 |
Why?
|
Adenosine | 1 | 2021 | 69 | 0.370 |
Why?
|
Molecular Targeted Therapy | 2 | 2024 | 120 | 0.370 |
Why?
|
Adaptive Immunity | 3 | 2017 | 96 | 0.350 |
Why?
|
Specimen Handling | 2 | 2024 | 61 | 0.350 |
Why?
|
Dermatitis, Contact | 1 | 2010 | 12 | 0.340 |
Why?
|
Phototherapy | 5 | 2023 | 34 | 0.340 |
Why?
|
Apoptosis | 1 | 2015 | 1032 | 0.340 |
Why?
|
Dermatitis | 2 | 2023 | 27 | 0.330 |
Why?
|
B-Lymphocytes | 2 | 2018 | 549 | 0.330 |
Why?
|
Receptors, CCR6 | 2 | 2022 | 10 | 0.330 |
Why?
|
Thrombosis | 1 | 2021 | 181 | 0.320 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2021 | 167 | 0.320 |
Why?
|
Exophiala | 1 | 2008 | 1 | 0.320 |
Why?
|
Clonal Anergy | 2 | 2009 | 23 | 0.320 |
Why?
|
Leg Dermatoses | 1 | 2008 | 3 | 0.320 |
Why?
|
Dermatomycoses | 1 | 2008 | 13 | 0.310 |
Why?
|
Kidney Transplantation | 1 | 2021 | 312 | 0.310 |
Why?
|
Oxidative Stress | 2 | 2021 | 279 | 0.280 |
Why?
|
gp100 Melanoma Antigen | 2 | 2020 | 5 | 0.280 |
Why?
|
Phenotype | 3 | 2021 | 1136 | 0.270 |
Why?
|
Transcriptome | 2 | 2024 | 338 | 0.260 |
Why?
|
Janus Kinase 1 | 2 | 2023 | 10 | 0.260 |
Why?
|
Janus Kinases | 2 | 2022 | 17 | 0.260 |
Why?
|
Cytokines | 3 | 2023 | 904 | 0.250 |
Why?
|
Inflammation | 4 | 2023 | 1094 | 0.250 |
Why?
|
STAT1 Transcription Factor | 2 | 2016 | 35 | 0.250 |
Why?
|
Case-Control Studies | 2 | 2020 | 1051 | 0.250 |
Why?
|
Lymphocyte Activation | 3 | 2018 | 743 | 0.240 |
Why?
|
Administration, Oral | 2 | 2017 | 356 | 0.240 |
Why?
|
Consensus | 3 | 2021 | 193 | 0.240 |
Why?
|
Interleukin-17 | 2 | 2017 | 88 | 0.230 |
Why?
|
Skin Cream | 2 | 2022 | 3 | 0.230 |
Why?
|
RNA, Small Interfering | 4 | 2023 | 855 | 0.230 |
Why?
|
Interleukin-4 | 1 | 2024 | 145 | 0.230 |
Why?
|
Skin Physiological Phenomena | 2 | 2014 | 16 | 0.220 |
Why?
|
Bleomycin | 2 | 2023 | 32 | 0.220 |
Why?
|
Photochemotherapy | 1 | 2023 | 20 | 0.220 |
Why?
|
Sequence Analysis, RNA | 1 | 2024 | 159 | 0.210 |
Why?
|
Uncertainty | 1 | 2023 | 33 | 0.210 |
Why?
|
Fibrosis | 2 | 2023 | 153 | 0.210 |
Why?
|
RNA, Double-Stranded | 1 | 2023 | 106 | 0.210 |
Why?
|
Ligands | 2 | 2023 | 410 | 0.210 |
Why?
|
Skin Transplantation | 1 | 2023 | 155 | 0.200 |
Why?
|
Dermatitis, Atopic | 1 | 2022 | 27 | 0.200 |
Why?
|
Proteomics | 1 | 2024 | 263 | 0.200 |
Why?
|
Cell Differentiation | 3 | 2016 | 1298 | 0.190 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2020 | 56 | 0.190 |
Why?
|
Tissue Distribution | 1 | 2022 | 287 | 0.190 |
Why?
|
Diagnosis, Differential | 1 | 2024 | 933 | 0.190 |
Why?
|
Autoantigens | 3 | 2021 | 129 | 0.190 |
Why?
|
Gene Ontology | 1 | 2021 | 38 | 0.190 |
Why?
|
Republic of Korea | 1 | 2021 | 29 | 0.180 |
Why?
|
CD28 Antigens | 2 | 2015 | 60 | 0.180 |
Why?
|
Epidemiologic Studies | 1 | 2021 | 33 | 0.180 |
Why?
|
Ointments | 1 | 2020 | 7 | 0.180 |
Why?
|
Piperidines | 2 | 2020 | 54 | 0.180 |
Why?
|
Aged | 6 | 2025 | 13412 | 0.180 |
Why?
|
Mice, Mutant Strains | 1 | 2021 | 297 | 0.180 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 250 | 0.180 |
Why?
|
Hyaluronan Receptors | 1 | 2020 | 35 | 0.180 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2020 | 45 | 0.180 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 140 | 0.170 |
Why?
|
Vaccinia virus | 1 | 2020 | 70 | 0.170 |
Why?
|
B7-H1 Antigen | 1 | 2020 | 54 | 0.170 |
Why?
|
Immunologic Factors | 1 | 2021 | 102 | 0.170 |
Why?
|
Genetic Testing | 1 | 2021 | 126 | 0.170 |
Why?
|
Cell Movement | 2 | 2019 | 428 | 0.160 |
Why?
|
Photography | 1 | 2019 | 40 | 0.160 |
Why?
|
Disease Susceptibility | 1 | 2020 | 157 | 0.160 |
Why?
|
Dermatologists | 1 | 2019 | 12 | 0.160 |
Why?
|
Transcription Factors | 2 | 2004 | 1470 | 0.160 |
Why?
|
Cell Death | 2 | 2018 | 271 | 0.160 |
Why?
|
Diagnostic Tests, Routine | 1 | 2019 | 42 | 0.160 |
Why?
|
Inflammasomes | 1 | 2023 | 324 | 0.160 |
Why?
|
Stem Cell Factor | 1 | 2018 | 26 | 0.150 |
Why?
|
Receptors, Interleukin-15 | 1 | 2018 | 2 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 475 | 0.150 |
Why?
|
Heat-Shock Proteins | 1 | 2018 | 65 | 0.150 |
Why?
|
Reactive Oxygen Species | 2 | 2016 | 201 | 0.150 |
Why?
|
Depression | 1 | 2025 | 828 | 0.150 |
Why?
|
Fas Ligand Protein | 1 | 2018 | 39 | 0.150 |
Why?
|
Pigmentation | 2 | 2015 | 25 | 0.150 |
Why?
|
Dendritic Cells | 1 | 2021 | 507 | 0.150 |
Why?
|
Early Growth Response Protein 2 | 2 | 2010 | 8 | 0.150 |
Why?
|
Child | 3 | 2023 | 4173 | 0.150 |
Why?
|
DNA | 2 | 2023 | 806 | 0.150 |
Why?
|
Disease Management | 1 | 2020 | 221 | 0.150 |
Why?
|
Foundations | 1 | 2018 | 8 | 0.150 |
Why?
|
Pigmentation Disorders | 1 | 2018 | 8 | 0.150 |
Why?
|
Cell Proliferation | 3 | 2014 | 940 | 0.150 |
Why?
|
Global Health | 1 | 2019 | 167 | 0.150 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 705 | 0.150 |
Why?
|
Follow-Up Studies | 1 | 2023 | 2337 | 0.140 |
Why?
|
Swine | 1 | 2018 | 352 | 0.140 |
Why?
|
Toll-Like Receptor 7 | 1 | 2018 | 95 | 0.140 |
Why?
|
Aged, 80 and over | 3 | 2023 | 5128 | 0.140 |
Why?
|
Phenylenediamines | 1 | 2017 | 5 | 0.140 |
Why?
|
Catechols | 1 | 2017 | 6 | 0.140 |
Why?
|
Hydroquinones | 1 | 2017 | 8 | 0.140 |
Why?
|
Pyrroles | 1 | 2017 | 45 | 0.140 |
Why?
|
Chemokine CXCL11 | 1 | 2017 | 4 | 0.140 |
Why?
|
Self Tolerance | 1 | 2017 | 19 | 0.140 |
Why?
|
Body Surface Area | 1 | 2017 | 11 | 0.140 |
Why?
|
Toll-Like Receptor 9 | 1 | 2018 | 197 | 0.140 |
Why?
|
Antigens, CD | 1 | 2018 | 341 | 0.140 |
Why?
|
Flow Cytometry | 1 | 2018 | 639 | 0.140 |
Why?
|
Receptors, CXCR4 | 1 | 2016 | 34 | 0.130 |
Why?
|
Lymphocytes | 1 | 2017 | 190 | 0.130 |
Why?
|
Regeneration | 1 | 2017 | 93 | 0.130 |
Why?
|
Combined Modality Therapy | 3 | 2023 | 355 | 0.130 |
Why?
|
ROC Curve | 1 | 2017 | 266 | 0.130 |
Why?
|
Gene-Environment Interaction | 1 | 2016 | 48 | 0.130 |
Why?
|
Immune Complex Diseases | 1 | 2016 | 2 | 0.130 |
Why?
|
Chemokine CXCL2 | 1 | 2016 | 14 | 0.130 |
Why?
|
Antigen-Antibody Complex | 1 | 2016 | 51 | 0.130 |
Why?
|
Risk | 1 | 2016 | 364 | 0.130 |
Why?
|
Bone Marrow Cells | 1 | 2016 | 231 | 0.130 |
Why?
|
Antioxidants | 1 | 2017 | 241 | 0.120 |
Why?
|
Insurance Coverage | 1 | 2015 | 94 | 0.120 |
Why?
|
Membrane Glycoproteins | 1 | 2018 | 660 | 0.120 |
Why?
|
International Classification of Diseases | 1 | 2015 | 132 | 0.120 |
Why?
|
Insurance, Health | 1 | 2015 | 133 | 0.120 |
Why?
|
Monocytes | 1 | 2016 | 343 | 0.120 |
Why?
|
Subcutaneous Fat | 1 | 2014 | 46 | 0.110 |
Why?
|
Immunity | 1 | 2014 | 100 | 0.110 |
Why?
|
Child, Preschool | 1 | 2019 | 1782 | 0.110 |
Why?
|
Scalp | 1 | 2013 | 29 | 0.110 |
Why?
|
Prospective Studies | 1 | 2021 | 3065 | 0.110 |
Why?
|
Wound Healing | 1 | 2014 | 174 | 0.110 |
Why?
|
Neutrophils | 1 | 2016 | 353 | 0.110 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 36 | 0.110 |
Why?
|
High Mobility Group Proteins | 1 | 2013 | 20 | 0.110 |
Why?
|
Up-Regulation | 2 | 2023 | 365 | 0.100 |
Why?
|
Risk Assessment | 1 | 2019 | 1920 | 0.100 |
Why?
|
Intestines | 1 | 2013 | 158 | 0.100 |
Why?
|
Renal Circulation | 1 | 2021 | 11 | 0.100 |
Why?
|
Adoptive Transfer | 1 | 2012 | 147 | 0.090 |
Why?
|
Methylation | 1 | 2021 | 123 | 0.090 |
Why?
|
Lymphocytic Choriomeningitis | 1 | 2010 | 53 | 0.090 |
Why?
|
Toxoplasmosis | 1 | 2010 | 20 | 0.090 |
Why?
|
Chronic Disease | 2 | 2023 | 716 | 0.080 |
Why?
|
DNA, Ribosomal Spacer | 1 | 2008 | 2 | 0.080 |
Why?
|
Itraconazole | 1 | 2008 | 13 | 0.080 |
Why?
|
DNA, Fungal | 1 | 2008 | 57 | 0.080 |
Why?
|
Culture Media | 1 | 2008 | 77 | 0.080 |
Why?
|
Interleukin-2 | 2 | 2009 | 164 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 357 | 0.080 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2009 | 146 | 0.070 |
Why?
|
Antifungal Agents | 1 | 2008 | 115 | 0.070 |
Why?
|
Microbial Sensitivity Tests | 1 | 2008 | 189 | 0.070 |
Why?
|
Cross-Sectional Studies | 2 | 2025 | 2373 | 0.070 |
Why?
|
Sequence Analysis, DNA | 1 | 2008 | 393 | 0.070 |
Why?
|
Molecular Sequence Data | 2 | 2008 | 1949 | 0.070 |
Why?
|
Zinc Fingers | 2 | 2004 | 96 | 0.070 |
Why?
|
Patient Health Questionnaire | 1 | 2025 | 5 | 0.060 |
Why?
|
Mice, Knockout | 3 | 2018 | 1985 | 0.060 |
Why?
|
Antigens, Ly | 2 | 2016 | 42 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2019 | 1561 | 0.060 |
Why?
|
CD3 Complex | 1 | 2004 | 62 | 0.060 |
Why?
|
Clone Cells | 1 | 2004 | 106 | 0.060 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 70 | 0.060 |
Why?
|
Cell Line | 2 | 2009 | 1968 | 0.060 |
Why?
|
Steroids | 1 | 2023 | 53 | 0.050 |
Why?
|
NLR Proteins | 1 | 2023 | 11 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2004 | 281 | 0.050 |
Why?
|
Ownership | 1 | 2022 | 17 | 0.050 |
Why?
|
Administration, Topical | 1 | 2022 | 47 | 0.050 |
Why?
|
Tacrolimus | 1 | 2022 | 62 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 40 | 0.050 |
Why?
|
Acne Vulgaris | 1 | 2022 | 23 | 0.050 |
Why?
|
Pruritus | 1 | 2022 | 29 | 0.050 |
Why?
|
Caspase 1 | 1 | 2023 | 107 | 0.050 |
Why?
|
Mice, Inbred BALB C | 2 | 2018 | 868 | 0.050 |
Why?
|
Interleukin-1 | 1 | 2023 | 156 | 0.050 |
Why?
|
Phosphorylation | 1 | 2004 | 882 | 0.050 |
Why?
|
Gene Silencing | 1 | 2004 | 378 | 0.050 |
Why?
|
Emollients | 1 | 2021 | 4 | 0.050 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2023 | 219 | 0.050 |
Why?
|
Age Factors | 1 | 2025 | 1504 | 0.050 |
Why?
|
Fibroblasts | 1 | 2023 | 377 | 0.050 |
Why?
|
Mental Health | 1 | 2023 | 335 | 0.040 |
Why?
|
Patient Selection | 1 | 2022 | 464 | 0.040 |
Why?
|
Cells, Cultured | 2 | 2016 | 2089 | 0.040 |
Why?
|
Health Personnel | 1 | 2023 | 340 | 0.040 |
Why?
|
Lighting | 1 | 2019 | 13 | 0.040 |
Why?
|
Reference Standards | 1 | 2019 | 71 | 0.040 |
Why?
|
International Cooperation | 1 | 2019 | 84 | 0.040 |
Why?
|
RNA | 1 | 2023 | 400 | 0.040 |
Why?
|
Internationality | 1 | 2019 | 43 | 0.040 |
Why?
|
Ultraviolet Rays | 1 | 2019 | 127 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 677 | 0.040 |
Why?
|
Observer Variation | 1 | 2019 | 205 | 0.040 |
Why?
|
Immune System | 1 | 2020 | 129 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 6071 | 0.040 |
Why?
|
RNA Interference | 1 | 2022 | 590 | 0.040 |
Why?
|
Ovalbumin | 1 | 2018 | 115 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2000 | 332 | 0.040 |
Why?
|
Program Evaluation | 1 | 2000 | 470 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 1547 | 0.040 |
Why?
|
Janus Kinase 3 | 1 | 2017 | 4 | 0.040 |
Why?
|
Autoantibodies | 1 | 2018 | 172 | 0.040 |
Why?
|
Th1 Cells | 1 | 2018 | 174 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2016 | 1464 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 243 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 81 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 75 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2000 | 606 | 0.030 |
Why?
|
Comorbidity | 1 | 2020 | 1078 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 441 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 673 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2000 | 844 | 0.030 |
Why?
|
Endotoxins | 1 | 2016 | 78 | 0.030 |
Why?
|
Mast Cells | 1 | 2016 | 41 | 0.030 |
Why?
|
Surveys and Questionnaires | 1 | 2023 | 2511 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2000 | 750 | 0.030 |
Why?
|
Neutrophil Infiltration | 1 | 2016 | 60 | 0.030 |
Why?
|
Regenerative Medicine | 1 | 2015 | 19 | 0.030 |
Why?
|
Smoking | 1 | 2000 | 826 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 119 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2016 | 168 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 445 | 0.030 |
Why?
|
Nurses | 1 | 2015 | 102 | 0.030 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2013 | 3 | 0.030 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 10 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 12 | 0.030 |
Why?
|
SOXC Transcription Factors | 1 | 2013 | 9 | 0.030 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 14 | 0.030 |
Why?
|
Interleukins | 1 | 2013 | 80 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2016 | 373 | 0.030 |
Why?
|
Rheology | 1 | 2013 | 71 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 70 | 0.030 |
Why?
|
Base Sequence | 2 | 2009 | 1300 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2013 | 188 | 0.020 |
Why?
|
Biomechanical Phenomena | 1 | 2013 | 242 | 0.020 |
Why?
|
Algorithms | 1 | 2017 | 976 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 146 | 0.020 |
Why?
|
Lung | 1 | 2016 | 913 | 0.020 |
Why?
|
Toxoplasma | 1 | 2010 | 32 | 0.020 |
Why?
|
Lymphocytic choriomeningitis virus | 1 | 2010 | 88 | 0.020 |
Why?
|
Macrophages | 1 | 2016 | 1000 | 0.020 |
Why?
|
Columbidae | 1 | 2009 | 11 | 0.020 |
Why?
|
Cytochromes c | 1 | 2009 | 26 | 0.020 |
Why?
|
Transplantation Tolerance | 1 | 2009 | 65 | 0.020 |
Why?
|
DNA Primers | 1 | 2009 | 289 | 0.020 |
Why?
|
Antigens | 1 | 2009 | 146 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2009 | 191 | 0.020 |
Why?
|
Transfection | 1 | 2009 | 675 | 0.020 |
Why?
|
Risk Factors | 1 | 2015 | 4982 | 0.020 |
Why?
|
Taxes | 1 | 2000 | 6 | 0.010 |
Why?
|
Snail Family Transcription Factors | 1 | 2000 | 28 | 0.010 |
Why?
|
Promyelocytic Leukemia Protein | 1 | 2000 | 15 | 0.010 |
Why?
|
Government Programs | 1 | 2000 | 20 | 0.010 |
Why?
|
Hydroxamic Acids | 1 | 2000 | 28 | 0.010 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2000 | 33 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2000 | 112 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2000 | 216 | 0.010 |
Why?
|
Histone Deacetylases | 1 | 2000 | 62 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2000 | 169 | 0.010 |
Why?
|
Risk-Taking | 1 | 2000 | 158 | 0.010 |
Why?
|
Health Surveys | 1 | 2000 | 298 | 0.010 |
Why?
|
RNA Splicing | 1 | 2000 | 159 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2000 | 194 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2000 | 277 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2000 | 349 | 0.010 |
Why?
|
Binding Sites | 1 | 2000 | 881 | 0.010 |
Why?
|
Prevalence | 1 | 2000 | 1252 | 0.010 |
Why?
|
Health Promotion | 1 | 2000 | 471 | 0.010 |
Why?
|
Prognosis | 1 | 2000 | 1599 | 0.010 |
Why?
|
Chromatin | 1 | 2000 | 599 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2000 | 541 | 0.010 |
Why?
|
Massachusetts | 1 | 2000 | 2003 | 0.010 |
Why?
|